Analysis of Influence Factors on Osteopenia in Different Treatment of Psoriasis

Inclusion Criteria * Adults aged 18 years or older. * Clinically confirmed diagnosis of psoriasis (with or without psoriatic arthritis). * Currently receiving one of the following treatments: TNF-α inhibitor (adalimumab), or IL-17A inhibitor (secukinumab). * Able and willing to undergo bone mineral density (BMD) assessment using dual-energy X-ray absorptiometry (DXA). * Signed informed consent provided. Exclusion Criteria * History of other systemic diseases affecting bone metabolism (e.g., primary hyperparathyroidism, severe chronic kidney disease, Cushing's syndrome). * Current use of medications known to strongly affect bone metabolism (e.g., long-term corticosteroids, bisphosphonates, denosumab, teriparatide). * Pregnant or breastfeeding women. * History of malignancy or other autoimmune diseases requiring systemic immunosuppressive therapy. * Inability to complete study visits, assessments, or provide informed consent.